Author(s): Stefanadis C, Toutouzas K, Vlachopoulos C, Tsioufis C, Synetos A,
Abstract Share this page
Abstract Renal artery denervation has recently emerged as a novel therapy for patients with resistant hypertension. Clinical results from renal sympathetic denervation support the safety and efficacy of this method over a period of 18 months. However, several limitations have been reported. Previous studies have shown that chemical denervation by vincristine is safe and effective in an experimental model. We describe the first-in-man application of chemical denervation with vincristine in a 74-year-old male patient with resistant arterial hypertension.
This article was published in Hellenic J Cardiol
and referenced in Medicinal chemistry